Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dog Diseases | 15 | 2025 | 60 | 4.240 |
Why?
|
| Osteosarcoma | 8 | 2025 | 59 | 3.430 |
Why?
|
| Bone Neoplasms | 6 | 2025 | 126 | 2.970 |
Why?
|
| Dogs | 23 | 2025 | 332 | 1.570 |
Why?
|
| Antineoplastic Agents | 8 | 2019 | 666 | 1.180 |
Why?
|
| Mouth Neoplasms | 1 | 2025 | 34 | 0.900 |
Why?
|
| Doxorubicin | 3 | 2024 | 101 | 0.800 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2025 | 68 | 0.730 |
Why?
|
| Pyrroles | 3 | 2016 | 52 | 0.690 |
Why?
|
| Indoles | 3 | 2016 | 115 | 0.670 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2019 | 32 | 0.610 |
Why?
|
| Neoplasms | 6 | 2023 | 1392 | 0.610 |
Why?
|
| Dystrophin | 1 | 2019 | 31 | 0.600 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 10 | 0.570 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2018 | 53 | 0.550 |
Why?
|
| Genomics | 5 | 2025 | 379 | 0.540 |
Why?
|
| Animals | 26 | 2025 | 20962 | 0.520 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 373 | 0.480 |
Why?
|
| Mutation | 3 | 2025 | 2629 | 0.470 |
Why?
|
| Splenic Neoplasms | 1 | 2015 | 8 | 0.460 |
Why?
|
| Hemangiosarcoma | 1 | 2015 | 25 | 0.450 |
Why?
|
| STAT3 Transcription Factor | 3 | 2022 | 72 | 0.430 |
Why?
|
| Whole Genome Sequencing | 3 | 2025 | 84 | 0.420 |
Why?
|
| Veterinary Medicine | 2 | 2019 | 5 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2018 | 34 | 0.270 |
Why?
|
| Carboplatin | 2 | 2019 | 43 | 0.270 |
Why?
|
| Sulfonamides | 2 | 2019 | 131 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 870 | 0.250 |
Why?
|
| DNA Copy Number Variations | 2 | 2025 | 71 | 0.240 |
Why?
|
| Cell Line, Tumor | 5 | 2022 | 1494 | 0.240 |
Why?
|
| Acrylamides | 2 | 2023 | 15 | 0.200 |
Why?
|
| Male | 12 | 2025 | 30295 | 0.190 |
Why?
|
| Cell Proliferation | 3 | 2022 | 1001 | 0.190 |
Why?
|
| Aminopyridines | 2 | 2023 | 36 | 0.180 |
Why?
|
| Histones | 1 | 2025 | 486 | 0.180 |
Why?
|
| Gene Deletion | 1 | 2022 | 312 | 0.170 |
Why?
|
| Administration, Oral | 2 | 2018 | 374 | 0.160 |
Why?
|
| Transcriptome | 1 | 2023 | 396 | 0.160 |
Why?
|
| Databases as Topic | 1 | 2019 | 51 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 869 | 0.150 |
Why?
|
| Data Mining | 1 | 2019 | 38 | 0.150 |
Why?
|
| Apoptosis | 2 | 2022 | 1094 | 0.150 |
Why?
|
| Drug Discovery | 1 | 2020 | 98 | 0.150 |
Why?
|
| Leukemia, Mast-Cell | 1 | 2018 | 1 | 0.150 |
Why?
|
| Hydrazines | 1 | 2018 | 10 | 0.150 |
Why?
|
| Pyrimidines | 1 | 2019 | 146 | 0.140 |
Why?
|
| Disease Models, Animal | 4 | 2023 | 2238 | 0.140 |
Why?
|
| Cell Line | 1 | 2022 | 2055 | 0.140 |
Why?
|
| Female | 12 | 2025 | 33351 | 0.140 |
Why?
|
| Lymphoma | 1 | 2018 | 103 | 0.140 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2018 | 65 | 0.130 |
Why?
|
| Hyperthermia, Induced | 1 | 2017 | 21 | 0.130 |
Why?
|
| Rhabdomyosarcoma | 1 | 2017 | 16 | 0.130 |
Why?
|
| Phototherapy | 1 | 2017 | 36 | 0.130 |
Why?
|
| Nanotubes | 1 | 2017 | 25 | 0.130 |
Why?
|
| Sarcoma, Ewing | 1 | 2017 | 15 | 0.130 |
Why?
|
| Vinblastine | 1 | 2016 | 18 | 0.130 |
Why?
|
| Pubic Bone | 1 | 2016 | 1 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 201 | 0.130 |
Why?
|
| Sarcoma, Experimental | 1 | 2016 | 6 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2018 | 5691 | 0.130 |
Why?
|
| Spinal Neoplasms | 1 | 2016 | 17 | 0.120 |
Why?
|
| Sacrum | 1 | 2016 | 27 | 0.120 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2016 | 43 | 0.120 |
Why?
|
| Pyrazines | 1 | 2016 | 35 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2019 | 368 | 0.120 |
Why?
|
| Benzamides | 1 | 2016 | 66 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 128 | 0.120 |
Why?
|
| Carbazoles | 1 | 2015 | 14 | 0.120 |
Why?
|
| Tramadol | 1 | 2015 | 16 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 106 | 0.120 |
Why?
|
| Piroxicam | 1 | 2015 | 3 | 0.120 |
Why?
|
| Gold | 1 | 2017 | 233 | 0.110 |
Why?
|
| Animals, Newborn | 1 | 2015 | 245 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 189 | 0.110 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 87 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 204 | 0.110 |
Why?
|
| Cells, Cultured | 1 | 2018 | 2176 | 0.100 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 695 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 410 | 0.080 |
Why?
|
| Phosphorylation | 3 | 2017 | 948 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2016 | 1540 | 0.070 |
Why?
|
| Triazoles | 2 | 2018 | 62 | 0.070 |
Why?
|
| B-Lymphocytes | 2 | 2024 | 571 | 0.070 |
Why?
|
| Anorexia | 2 | 2018 | 7 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 195 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 467 | 0.060 |
Why?
|
| Humans | 8 | 2023 | 64243 | 0.060 |
Why?
|
| Diarrhea | 2 | 2016 | 76 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 249 | 0.060 |
Why?
|
| Cell Survival | 2 | 2017 | 582 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2019 | 1019 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2024 | 14 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2023 | 68 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2024 | 3315 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2023 | 265 | 0.040 |
Why?
|
| Stem Cell Niche | 1 | 2020 | 17 | 0.040 |
Why?
|
| Information Technology | 1 | 2019 | 4 | 0.040 |
Why?
|
| Genetic Fitness | 1 | 2020 | 36 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2019 | 31 | 0.040 |
Why?
|
| Mice | 3 | 2018 | 11003 | 0.040 |
Why?
|
| Phylogeny | 1 | 2020 | 385 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2019 | 118 | 0.040 |
Why?
|
| Oncogenes | 1 | 2018 | 70 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2018 | 114 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 324 | 0.030 |
Why?
|
| Proteolysis | 1 | 2018 | 149 | 0.030 |
Why?
|
| Tumor Protein p73 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Lethargy | 1 | 2016 | 3 | 0.030 |
Why?
|
| Mast Cells | 1 | 2016 | 39 | 0.030 |
Why?
|
| Pelvic Floor | 1 | 2016 | 10 | 0.030 |
Why?
|
| Rectal Diseases | 1 | 2016 | 28 | 0.030 |
Why?
|
| Ureteral Obstruction | 1 | 2016 | 28 | 0.030 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2016 | 52 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 92 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 106 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 99 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 199 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 299 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 205 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 141 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 278 | 0.030 |
Why?
|
| Administration, Metronomic | 1 | 2015 | 2 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 1176 | 0.030 |
Why?
|
| Vomiting | 1 | 2016 | 138 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2016 | 201 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 517 | 0.030 |
Why?
|
| Neutropenia | 1 | 2015 | 69 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 215 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2016 | 486 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 309 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 498 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 423 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2015 | 348 | 0.030 |
Why?
|
| Weight Loss | 1 | 2016 | 273 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 205 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 534 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 944 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 457 | 0.020 |
Why?
|
| RNA Interference | 1 | 2016 | 618 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 1681 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 531 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 927 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 1669 | 0.020 |
Why?
|